|
Mirdametinib Clinical Trials
7 actively recruiting trials across 5 locations
No change since May 2026
Also known as: Gomekli, MEK Inhibitor PD0325901, PD 901, PD-0325901
Pipeline
Phase 2: 3Phase 1/2: 4
Top Sponsors
- Memorial Sloan Kettering Cancer Center2
- St. Jude Children's Research Hospital1
- National Cancer Institute (NCI)1
- Murdoch Childrens Research Institute1
- Kevin Kim, MD1
Indications
- Cancer7
- Progressive Low-Grade Glioma1
- Recurrent Low-Grade Glioma1
- Monotherapy1
- Myxoid Pleomorphic Liposarcoma1
Basking Ridge, New Jersey2 trials
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Phase 1/2
A Study of Mirdametinib in People With Central Nervous System Tumors
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 1/2
Other1 trial
Duarte, California1 trial
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
City of Hope Comprehensive Cancer Center
Phase 2
San Francisco, California1 trial
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
California Pacific Medical Center - Sutter Health
Phase 2
Baltimore, Maryland1 trial
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Johns Hopkins Hospital
Phase 1/2
Memphis, Tennessee1 trial
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.